TA Research predicts a recovery in Duopharma's CHC segment a...
TA Research predicts a recovery in Duopharma's CHC segment and increased sales to the government sector in 2024. They also foresee higher volumes and pricing from the new APPL contract, and a rise in the Insulin contract contribution to RM90mil in FY24.
Duopharma Earnings Set to Improve This Year
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3556Followers
0Following
8388Visitors
Follow